CollaGenex at outperform by RBC

RBC Capital Markets analyst Ken Trbovich rated CollaGenex Pharmaceuticals, Inc. at outperform, speculative risk, after the Food and Drug Administration approved Oracea for the treatment of rosacea. RBC believes the only FDA-approved oral treatment for rosacea will have sales of $7 million this year and $60 million next year, with peak sales of around $100 million in 2008-2009. Shares of the Newton, Pa., pharmaceutical company were up 82 cents, or 7.02%, at $12.50 on volume of 3,175,181 shares versus the three-month running average of 130,131 shares. (Nasdaq: CGPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.